Supernus Pharmaceuticals EBITDA Margin 2011-2024 | SUPN

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Supernus Pharmaceuticals (SUPN) over the last 10 years. The current EBITDA margin for Supernus Pharmaceuticals as of June 30, 2024 is .
Supernus Pharmaceuticals EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2024-06-30 $0.63B $0.11B 17.94%
2024-03-31 $0.60B $0.07B 12.21%
2023-12-31 $0.61B $0.08B 12.99%
2023-09-30 $0.61B $0.11B 18.66%
2023-06-30 $0.63B $0.11B 16.88%
2023-03-31 $0.67B $0.14B 20.81%
2022-12-31 $0.67B $0.14B 20.54%
2022-09-30 $0.66B $0.11B 16.08%
2022-06-30 $0.63B $0.13B 20.32%
2022-03-31 $0.60B $0.14B 22.80%
2021-12-31 $0.58B $0.14B 23.49%
2021-09-30 $0.56B $0.16B 29.08%
2021-06-30 $0.57B $0.18B 32.05%
2021-03-31 $0.56B $0.19B 34.65%
2020-12-31 $0.52B $0.21B 39.54%
2020-09-30 $0.48B $0.20B 41.51%
2020-06-30 $0.42B $0.18B 41.98%
2020-03-31 $0.40B $0.17B 42.79%
2019-12-31 $0.39B $0.17B 42.60%
2019-09-30 $0.41B $0.17B 41.18%
2019-06-30 $0.41B $0.17B 40.83%
2019-03-31 $0.40B $0.16B 39.11%
2018-12-31 $0.41B $0.16B 39.61%
2018-09-30 $0.38B $0.15B 39.90%
2018-06-30 $0.36B $0.14B 37.99%
2018-03-31 $0.33B $0.12B 37.13%
2017-12-31 $0.30B $0.11B 35.43%
2017-09-30 $0.28B $0.09B 31.88%
2017-06-30 $0.25B $0.08B 32.41%
2017-03-31 $0.23B $0.07B 29.26%
2016-12-31 $0.22B $0.06B 26.51%
2016-09-30 $0.20B $0.05B 24.37%
2016-06-30 $0.18B $0.03B 18.44%
2016-03-31 $0.16B $0.03B 15.34%
2015-12-31 $0.15B $0.02B 14.86%
2015-09-30 $0.14B $0.02B 14.81%
2015-06-30 $0.12B $0.01B 11.76%
2015-03-31 $0.11B $0.02B 13.27%
2014-12-31 $0.09B $-0.00B -2.15%
2014-09-30 $0.07B $-0.02B -25.00%
2014-06-30 $0.05B $-0.03B -68.00%
2014-03-31 $0.02B $-0.05B -270.00%
2013-12-31 $0.01B $-0.06B -536.36%
2013-09-30 $0.00B $-0.06B -3050.00%
2013-06-30 $0.00B $-0.06B -5700.00%
2013-03-31 $0.00B $-0.05B -5100.00%
2012-12-31 $0.00B $-0.04B -4100.00%
2012-09-30 $0.00B $-0.04B inf%
2012-06-30 $0.00B $-0.04B inf%
2012-03-31 $0.00B $-0.04B -3600.00%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.872B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00